Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars and Biologics.
This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including:
- Legislative/regulatory issues, including the biosimilars act and anticipated FDA guidelines
- The safety, efficacy, and interchangeability of biologics
- The science and analytical chemistry associated with the manufacture of biologics
- Needed pharmacovigilance and adverse effect reporting systems
- Formulary management